Verralab Ja LLC

Verralab Ja LLC was paid $38.82M by Medicaid between Jan 2018 and Jun 2023, across 109 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 78% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#3 of 73

Median peer was paid$95K

This provider vs. median409×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	124,874	$9.39M
2019	110,184	$9.00M
2020	128,617	$5.88M
2021	154,987	$6.31M
2022	101,740	$5.48M
2023	50,565	$2.76M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	78%	285,809	145,330	$30.19M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	4.5%	19,417	14,462	$1.76M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.6%	14,124	12,003	$1.02M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.8%	10,837	7,293	$714K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.8%	10,326	6,015	$696K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.1%	21,715	20,471	$435K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	1.1%	21,768	20,453	$426K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.1%	21,715	20,470	$426K
87563		1.0%	19,815	18,659	$399K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	8,335	6,084	$320K
87150		<1%	4,416	2,786	$292K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	15,806	14,912	$212K

97 more codes

81226		<1%	466	$141K
86803		<1%	15,202	$122K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,253	$97K
86705		<1%	14,697	$96K
80053	Comprehensive metabolic panel	<1%	16,730	$95K
86780		<1%	12,069	$91K
81225		<1%	466	$91K
87340		<1%	14,873	$84K
84443	Thyroid stimulating hormone (TSH)	<1%	9,731	$84K
87481		<1%	3,412	$79K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	16,371	$69K
87500		<1%	4,639	$69K
87522	Neg quan hep c or qual rna	<1%	2,513	$64K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	5,008	$58K
81227		<1%	466	$54K
81328		<1%	468	$54K
81230		<1%	468	$54K
81231		<1%	468	$54K
87653		<1%	3,403	$42K
87521	Neg quan hep c or qual rna	<1%	1,949	$38K
80305		<1%	4,661	$37K
86704		<1%	4,749	$34K
86706		<1%	4,919	$31K
81355		<1%	466	$27K
87581		<1%	1,238	$27K
87486		<1%	1,238	$27K
81241		<1%	466	$24K
87640		<1%	3,401	$22K
36415	Collection of venous blood by venipuncture	<1%	19,023	$21K
81240		<1%	466	$20K
81291		<1%	466	$20K
81025		<1%	2,397	$20K
80050	General health panel	<1%	442	$12K
80074		<1%	636	$10K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,637	$9K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	608	$8K
84439		<1%	1,465	$8K
80061	Lipid panel	<1%	942	$7K
82607		<1%	670	$6K
87902		<1%	19	$3K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	586	$2K
86709		<1%	298	$2K
83992		<1%	1,025	$1K
80048	Basic metabolic panel (calcium, ionized)	<1%	294	$1K
80373		<1%	1,324	$1K
80372		<1%	1,034	$972.95
80365		<1%	1,312	$846.85
80361		<1%	1,311	$840.35
80346		<1%	1,258	$832.39
80360		<1%	1,290	$831.55
80349		<1%	1,292	$818.87
80354		<1%	1,314	$818.83
80358		<1%	1,309	$814.66
86592		<1%	333	$810.28
80353		<1%	1,290	$809.68
80359		<1%	1,268	$778.69
80348		<1%	1,313	$734.49
80356		<1%	1,112	$727.30
80371		<1%	1,062	$703.83
82746		<1%	79	$679.57
80364		<1%	1,057	$657.44
80323		<1%	895	$654.90
80350		<1%	1,008	$646.26
81596		<1%	39	$545.05
80345		<1%	931	$515.70
80355		<1%	882	$493.25
80369		<1%	674	$484.86
80366		<1%	893	$472.46
80368		<1%	625	$469.95
86708		<1%	60	$436.38
80324		<1%	1,122	$435.77
83540		<1%	106	$370.22
80325		<1%	131	$327.44
80367		<1%	1,001	$279.07
80357		<1%	88	$257.62
82728		<1%	28	$203.95
84481		<1%	20	$202.94
80337		<1%	507	$180.65
84702		<1%	23	$175.31
84153		<1%	17	$132.94
84154		<1%	17	$126.50
80370		<1%	35	$124.07
83735		<1%	31	$115.19
80334		<1%	356	$109.01
84703		<1%	23	$94.94
83550		<1%	26	$85.65
80076		<1%	15	$82.83
80363		<1%	152	$70.60
80178		<1%	13	$46.11
81406		<1%	36	$44.00
81479	Unlisted molecular pathology procedure	0%	465	$0.00
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	0%	2,129	$0.00
82570		0%	2,516	$0.00
99499		0%	252	$0.00
80321		0%	15	$0.00
84311		0%	2,512	$0.00
83986		0%	2,519	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialREYNOLDS, KRISTEN (PRESIDENT)